Service Contract Extension

DEPARTMENT OF THE NAVY, NAVAL MEDICAL LOGISTICS COMMAND SYNOPSIS AND SOLICITATION The Naval Medical Logistics Command intends to negotiate on a sole source basis (IAW FAR 13.501) with AGFA, 55 S Cummings Drive, Middletown DE 19709, 302-376-5668., as the only responsible source that can provide a month long logical follow on an existing AGFA CR service contract in the time frame that is required Sept 30 to Nov 1, 2009. This acquisition is being conducted under simplified acquisition procedures FAR 13.501 under the authority of the test program for commercial items (section 4202 of the Clinger-Cohen Act of 1996). There are not set-aside restrictions for this requirement. The intended procurement will be classified under North America Industry Classification System (NAICS) 333315. This notice of intent is not a request for competitive proposals and no solicitation document exists for this requirement. However, parties interested in responding to this notice will need to submit technical data, including cost, sufficient to determine capability in providing the same product. All capability statements received by the closing date of this synopsis will be considered by the Government. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Capability statements shall be submitted by email only as a MS Word or Adobe PDF attachment to [email protected] . No phone calls accepted. ESSENTIAL CHARACTERISTICS CR Contract Extension National Naval Medical Center Bethesda has a requirement for a logical follow on an AGFA CR service contract for their AGFA CR systems. The contract shall be from Sept 30 to Nov 1, 2009. The contract shall be staffed with personnel that are cleared to work in a secure environment. The system shall be compliant with the Food and Drug Administration (FDA) requirements to market and deliver medical products for use in the United States of America, even should delivery be requested outside of the United States. The claims made for the product shall comply with the regulations of the FDA with respect to products for marketing and delivery of a medical product for use in the United States of America, even should delivery be requested outside of the United States.